Previous 10 | Next 10 |
2024-06-07 07:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed. The markets didn&...
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D....
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The ...
2024-05-20 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem befor...
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clin...
2024-05-13 16:38:34 ET More on Atossa Therapeutics Atossa stock climbs 11% on breast cancer drug data ATOS, SMR and EIGR are among pre market gainers Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics ...
2024-05-13 14:15:01 ET H.C. Wainwright analyst issues BUY recommendation for ATOS on May 13, 2024 12:29PM ET. The previous analyst recommendation was Buy. ATOS was trading at $1.4817 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May ...
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screeni...
2024-04-29 09:32:57 ET More on Atossa Therapeutics Atossa stock climbs 11% on breast cancer drug data ATOS, SMR and EIGR are among pre market gainers Seeking Alpha’s Quant Rating on Atossa Therapeutics Historical earnings data for Atossa Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...